Ixifi

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Ixifi is used to treat autoimmune disorders including certain kinds of arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis. Can increase the risk of developing serious infections.

Ixifi Overview

Reviewed: January 11, 2018
Updated: 

Ixifi is a prescription medication used to treat certain inflammatory bowel diseases, arthritis, and psoriasis in patients over 6 years of age.

Ixifi belongs to a group of drugs called tumor necrosis factor (TNF) blocker medications. Ixifi blocks the action of a protein in your body called tumor necrosis factor-alpha (TNF-alpha). TNF-alpha is made by your body's immune system. People with certain diseases have too much TNF-alpha that can cause the immune system to attack normal healthy parts of the body. Ixifi can block the damage caused by too much TNF-alpha.

This medication is available in an injectable form to be given directly into a vein by a healthcare professional. It is given over a period of about 2 hours.
 
Common side effects of Ixifi include upper respiratory infections, infusion-related reactions, headache, and stomach pain.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Ixifi Drug Class

Back to Top

Ixifi is part of the drug class:

Ixifi FDA Warning

Back to Top

WARNING: SERIOUS INFECTIONS and MALIGNANCY

  • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens.
  • Discontinue Ixifi if a patient develops a serious infection.
  • Perform test for latent TB; if positive, start treatment for TB prior to starting IXIFI. Monitor all patients for active TB during treatment, even if initial latent TB test is negative.
  • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products.
  • Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of IXIFI cases were reported in patients with Crohn’s disease or ulcerative colitis, most of whom were adolescent or young adult males.